Bulletin
Investor Alert

Topics

Food and Drug Administration

4:32 a.m. April 7, 2021 - By Tomi Kilgore
Anthem to provide employees with an incentive to be fully vaccinated against COVID-19Anthem Inc. said Wednesday it will provide an incentive to any of its employees who are fully vaccinated against COVID-19. The health insurer said the incentive will be in the form of a one-time credit toward medical premiums or a donation to the Anthem Cares Fund that helps support fellow employees in need, at the employees choice. "Anthem is committed to empowering our associates to live a healthy lifestyle, therefore it was important that we provided an incentive to those who receive the COVID-19 vaccination. I am impressed and grateful for everything our associates have done and continue to do for the customers and communities we serve," said Chief Human Resources Officer Leah Stark. There are currently three COVID-19 vaccines that have been granted emergency use authorization by the Food and Drug Administration, two-dose vaccines from Pfizer Inc. and partner BioNTech SE and Moderna Inc. , and Johnson & Johnson's one-dose vaccine. Anthem's stock, which was indicated down 0.4% in premarket trading, has rallied 9.7% year to date while the S&P 500 has gained 8.5%. (This replaces an earlier item that removes the dollar amount of the incentive provided by the company, after the company said the amount noted in a previous release resulted from a "publishing mistake.")
4:40 a.m. March 26, 2021 - By Ciara Linnane
GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentGlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for mild-to-moderate COVID-19 in adults and adolescents aged 12 and older who are at risk of hospitalization or death. The companies said early data from a Phase 3 trial found the treatment showed an 85% reduction in hospitalization or death compared to placebo. There were 583 patients enrolled in the trial. Vir shares slid 0.8% premarket, but have gained 97% in the year to date, while the S&P 500 has gained 4%.
4:35 a.m. March 24, 2021 - By Tomi Kilgore
Second Sight Medical stock tumbles after private placement of stock at 46% discountShares of Second Sight Medical Products Inc. tumbled 25% to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private placement of common stock. The share sale comes after more than 6-fold month to date through Tuesday, after the company's Argus 2s Retinal Prosthesis System was . The company said earlier Wednesday that it will issue 4.65 million shares, which represents about 20% of the shares outstanding, at a price of $6.00, which is 45.5% below Tuesday's closing price of $11.01, for gross proceeds of $27.9 million. The company expects to use the proceeds for working capital. The stock has soared 488.8% year to date through Tuesday, while the S&P 500 has gained 4.1%.
7:33 a.m. March 4, 2021 - By Tomi Kilgore
Moderna, IBM explore blockchain tech, AI to support 'smarter' management of COVID-19 vaccinesModerna Inc. and International Business Machines Corp. announced Thursday plans to work together to find technologies to support "smarter COVID-19 vaccine management." The technologies the companies will explore include artificial intelligence, blockchain and hybrid cloud, the companies said. "Moderna is committed to working with a coalition of partners to increase education and awareness of the importance of vaccination to help defeat COVID-19," said Michael Mullette, a managing director of North America commercial operations at Moderna. "We look forward to working with IBM to apply digital innovations to build connections between organizations, governments, and individuals to instill confidence in COVID-19 vaccines." Moderna's stock rose 1.6% in midday trading and IBM shares fell 0.7%, while the Dow Jones Industrial Average gained 118 points, or 0.4%. Moderna currently has one of three COVID-19 vaccines granted emergency use authorization by the Food and Drug Administration, the others being from Pfizer Inc. and BioNTech SE and Johnson & Johnson .
9:47 a.m. Feb. 23, 2021 - By Tomi Kilgore
Meridian Bioscience issues correction: It can't ship its Revogene SARS-CoV-2 test until EUA is grantedMeridian Bioscience Inc. issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7%, and has now tumbled 30.0% since it closed on Feb. 11 at the highest price since October 2008. After speaking with the Food and Drug Administration mid-morning Tuesday, the company said it will not be able to distribute its Revogene SARS-CoV-2 test until the test receives Emergency Use Authorization approval from the FDA. Earlier Tuesday, the company had said it would resume shipping of the tests once it notifies the FDA of its intent to re-submit an EUA application. The company said Tuesday that it had decided to withdraw its EUA application following further discussions with the FDA, which comes a week after the company said the FDA requested additional information on the test. Despite the recent selloff, Meridian's stock has still climbed 19.5% over the past three months, while the S&P 500 has gained 7.7%.
4:19 a.m. Jan. 26, 2021 - By Ciara Linnane
Moderna on track to deliver 200 million doses of its COVID vaccine to U.S. govt by end-JuneModerna Inc. said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.-based biotech said it has already delivered more than 30 million doses of the vaccine to the U.S. government. About 10.1 million doses of the vaccine have by now been administered in the U.S., the company said, citing Centers for Disease Control and Prevention data. The vaccine was granted emergency use authorization by the U.S. Food and Drug Administration on Dec. 18, shortly after a separate vaccine developed by Pfizer Inc. and its German partner BioNTech SE won the same authorization. The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. The vaccine has also been authorized for use in Canada, Israel, the European Union, the U.K. and Switzerland. Moderna shares were down 1.2% premarket, but have gained 596% in the last 12 months, while the SPDR S&P Biotech ETF has gained 73% and the S&P 500 has gained 17%.
4:16 a.m. Jan. 12, 2021 - By Tomi Kilgore
Uber, Moderna to collaborate on supporting COVID-19 vaccine uptakeUber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. The ridesharing and delivery company and the biotech said they will work together to provide "credible information" on vaccine safety through Uber's in-app messaging, and will look to identify opportunities to broaden access to COVID-19 vaccines. Moderna's COVID-19 vaccine was authorized in December for emergency use by the Food and Drug Administration, along with a vaccine from Pfizer Inc. and BioNTech SE , but the . "As part of our commitment to help address COVID-19, Moderna will be working with a coalition of partners to educate, build trust around and increase awareness of the importance of vaccination in those communities significantly impacted by the pandemic," said Moderna Chief Executive Stéphane Bancel. "We look forward to combining our expertise with Uber's capabilities and platform to support this important effort." Uber's stock rose 1.5% in premarket trading Tuesday and Moderna shares advanced 0.8%, while futures for the S&P 500 edged up 0.2%.
10:19 a.m. Jan. 5, 2021 - By Ciara Linnane
January will be worst month for U.S. pandemic so far with post-holiday travel cases seen surging U.S. sets fresh record for hospitalizations and Los Angeles County says a COVID-19 patient is dying every 15 minuteshe number of global cases of the coronavirus-borne illness COVID-19 edged toward 86 million on Tuesday and the U.S. set yet another record for hospitalizations, as experts warned that January will likely be the worst month of the pandemic so far due to a surge in new infections after holiday travel.
10:56 a.m. Jan. 4, 2021 - By Ciara Linnane
U.S. heads toward 21 million COVID-19 cases and 353,000 deaths as vaccine program continues to lag all targets ‘Last mile’ vaccine distribution has been far slower than required, ‘with millions of doses still sitting on the shelves,’ says Raymond James analystThe global case tally for the coronavirus-borne illness COIVID-19 climbed above 85 million on Monday, as the U.S. headed toward 21 million cases and 353,000 deaths, as the vaccine program continued to advance with fits and starts and to lag all early targets.
2:05 a.m. Dec. 29, 2020 - By Ciara Linnane
Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion Companies are also seeking approval for drug as treatment for unmet women’s health needsShares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health in a deal worth up to $4.2 billion in upfront and potential milestone payments.
4:33 a.m. Dec. 28, 2020 - By Ciara Linnane
UPDATE: Myovant shares soar 20% premarket on news of Pfizer cancer drug deal worth up to $4.2 billionShares of Myovant Sciences soared 20% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a deal worth up to $4.2 billion in upfront and potential milestone payments. Myovant will receive an upfront payment of $650 million to develop relugolix, a once-daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women's health in the U.S. and Canada. Pfizer will have the exclusive right to commercialize relugolix in oncology outside the U.S. and Canada, excluding some Asian countries. Myovant is one of five companies under the Sumitovant umbrella. "Myovant and Pfizer will jointly develop and commercialize ORGOVYX(TM) (relugolix) in advanced prostate cancer and, if approved, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women's health in the U.S. and Canada," the companies said in a joint statement. The U.S. Food and Drug Administration approved Orgovyx on Dec. 18 as a treatment for advanced prostate cancer. Pfizer shares were slightly higher premarket and have gained 0.4% in the year to date, while the S&P 500 has gained 15%.
2:18 a.m. Dec. 7, 2020 - By Quentin Fottrell
Joe Biden’s pandemic plan: Restore Obamacare, mandatory masks, paid sick leave and free COVID-19 tests The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face’The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face.’
4:08 a.m. Dec. 4, 2020 - By Ciara Linnane
Eli Lilly and UnitedHealth to study Lilly's antibody treatment bamlanivimab in high-risk COVID patients Eli Lilly & Co. and UnitedHealth Group Inc. said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. Food and Drug Administration emergency use authorization as a treatment for mild to moderate COVID-19 patients, who are at high risk of getting a severe case of the virus and/or requiring hospitalization. "The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations ," the companies said in a joint statement. "Larger pragmatic studies in diverse populations can help us further understand the efficacy and safety of SARS-CoV-2 neutralizing antibodies in real world settings," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. Eli Lilly shares were not active premarket, while UnitedHealth was slightly higher.
2:31 a.m. Dec. 1, 2020 - By Tomi Kilgore
Pfizer, BioNTech apply for CMA in Europe for COVID-19 vaccine candidateShares of Pfizer Inc. rallied 2.8% while Germany-based BioNTech SE dropped 2.5% in premarket trading Tuesday, after the company said they submitted their COVID-19 vaccine candidate BNT162b2 for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA). If the EMA recommends granting a CMA, that could lead to use of BNT162b2 in Europe before the end of 2020. The companies had to the Food and Drug Administration on Nov. 20. On Monday, Moderna Inc. , and said it will apply for CMA with the EMA. Shares of Pfizer have gained 9.7% over the past three months and BioNTech's stock has rocketed 114.9%, while the S&P 500 has edged up 2.7%.
4:58 a.m. Nov. 16, 2020 - By Quentin Fottrell
‘Help is coming — and it’s coming soon’: Dr. Fauci outlines when COVID-19 vaccine will be available to all Americans ‘When we get both of those things together — vaccine and public health measures — that would really be a game changer,’ says government’s top infectious-diseases expertInfectious disease expert Dr. Anthony Fauci said: ‘When we get both of those things together — vaccine and public health measures — that would really be a game changer.’
9:47 a.m. Nov. 9, 2020 - By Quentin Fottrell
Joe Biden announces his COVID-19 task force The team of public-health experts will advise the Biden administration and the transition’s COVID-19 staffThe team of public-health experts will advise the Biden administration and the transition’s COVID-19 staff.
5:36 a.m. Oct. 31, 2020 - By Ciara Linnane
Coronavirus update: U.S. counts almost 100,000 cases in new one-day record; The Lancet says Trump pandemic response is ‘disastrous’ USA Today poll finds most Americans disapprove of Trump’s campaign rallies, prefer Biden’s more discreet approachThe U.S. death toll from the coronavirus illness COVID-19 headed toward 230,000 on Saturday and cases topped 9 million after more than 99,000 infections were counted in a record one-day tally, with infections climbing in all swing states just days ahead of the presidential election.
7:46 a.m. Oct. 29, 2020 - By Ciara Linnane
Coronavirus update: U.S. continues to set new case records as Trump remains insistent that U.S. has ‘rounded the corner’ New COVID-19 cases are rising in 47 states, and 27 states recorded 1,000 or more new diagnoses in the last 24 hoursThe U.S. death toll from the coronavirus illness COVID-19 edged closer to 228,000 on Thursday and more than 81,000 new infections were recorded in a single day, pushing the seven-day tally to record highs.
4:31 a.m. Oct. 8, 2020 - By Jaimy Lee
Regeneron's stock rallies after it announces EUA request for antibody treatmentShares of Regeneron Pharmaceuticals Inc. were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody treatment. The therapy was prescribed to President Donald Trump last week as part of his COVID-19 treatment plan; on Wednesday, in a video, (He d Gilead Sciences Inc.'s remdesivir and the steroid dexamethasone.) Regeneron's announcement to file for an emergency use authorization (EUA) came the same day that Eli Lilly & Co. , which is also developing an antibody treatment for mild to moderate COVID-19 patients, announced Wednesday morning . Regeneron's stock is up 57.6% so far this year. The S&P 500 , in comparison, has gained 5.8%.
10:29 a.m. Sept. 28, 2020 - By Ciara Linnane
Coronavirus update: Global death toll inches toward 1 million as hot spots emerge in India, Europe, South America and Israel U.S. confirmed cases top 7 million as President Trump gears up for update on testing strategy; CDC head says new task force member is spreading misinformation, NBC reportsThe global death toll from the coronavirus that causes COVID-19 edged closer to a million on Monday, and India marked the grim milestone of more than six million confirmed cases, placing it second to the U.S. by case numbers.
11:59 a.m. Sept. 8, 2020 - By Ciara Linnane
Coronavirus update: Global case tally tops 27.3 million, and U.S. accounts for a quarter, as 9 drug-company CEOs pledge to ‘stand with science’ in vaccine development Vaccine makers will only submit for full FDA approval or emergency-use authorization ‘after demonstrating safety and efficacy through a Phase 3 clinical study,’ the CEO group pledgesThe number of confirmed cases of the coronavirus that causes COVID-19 climbed above 27.3 million on Tuesday with the U.S. accounting for about a quarter of that total, as a group of nine drugmakers pledged to “stand with science” in developing a vaccine.
2:36 a.m. Sept. 3, 2020 - By Ciara Linnane
Coronavirus update: Global case tally nears 26 million, and experts are alarmed that U.S. isn’t joining WHO vaccine effort ‘This go-it-alone approach leaves America at risk of not getting a vaccine,’ says one expertThe number of confirmed cases of the coronavirus that causes COVID-19 worldwide edged closer to 26 million on Wednesday, as experts sounded the alarm on the Trump administration’s decision not to work with an international effort to develop and distribute a COVID-19 vaccine that is backed by the World Health Organization.
10:40 a.m. Aug. 31, 2020 - By Ciara Linnane
Coronavirus update: U.S. case tally climbs above 6 million and FDA head says he won’t be pressured to rush out a vaccine ‘This is going to be a science, medicine, data decision. This is not going to be a political decision,’ says Dr. Stephen HahnThe number of confirmed U.S. cases of the coronavirus that causes COVID-19 edged above 6 million on Monday, and the head of the U.S. Food and Drug Administration said he would not be pressured to rush out a vaccine by President Donald Trump before the November presidential election.
11:22 a.m. Aug. 27, 2020 - By Ciara Linnane
Coronavirus update: Global case tally tops 24 million as U.S. tally tops 5.8 million, and CDC head walks back testing change amid outcry In a second embarrassment for a major U.S. public health agency this week, CDC says asymptomatic people exposed to infection can again be testedThe number of confirmed cases of the coronavirus illness COVID-19 worldwide climbed above 24 million on Thursday, and the U.S. tally topped 5.8 million, as the head of the Centers for Disease Control and Prevention walked back a change in guidelines on testing following a storm of criticism from doctors and scientists.
11:46 p.m. Aug. 18, 2020 - By Steve Goldstein
Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos saysGilead Sciences investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S. Food and Drug Administration in current form, its partner Galapagos said. The FDA wants further data and has expressed concerns about the overall benefit/risk profile of the 200 mg dose, said Galapagos. Galapagos is entitled to an approval milestone of $100 million for the approval of filgotinib in the U.S., and as a result Galapagos revised its 2020 operational cash burn guidance to between €490 and €520 million.
4:38 a.m. Aug. 12, 2020 - By Ciara Linnane
Russia’s accelerated COVID-19 vaccine greeted with alarm as experts say Phase 3 trial is essential ‘The goal isn’t to be first, it’s to be first in a way that gives people faith in a vaccine’s safety,’ says one expertNews that Russia has registered the first vaccine to treat COVID-19 before starting and completing Phase 3 trials was greeted with alarm on Tuesday, with experts concerned it may come with safety issues that could stoke antivaccination and anti-science sentiment.
2:40 a.m. July 23, 2020 - By Ciara Linnane
Coronavirus update: U.S. case tally climbs above 3.9 million and Trump’s late move on face masks criticized by health experts The pandemic ‘will probably, unfortunately, get worse before it gets better.’ Trump reverses course on pandemic he called a hoaxThe number of U.S. cases of the coronavirus illness COVID-19 climbed above 3.9 million on Wednesday, a day after President Donald Trump finally encouraged Americans to wear face masks in public, marking a break with his approach to the pandemic thus far.
11:07 a.m. July 7, 2020 - By Ciara Linnane
Coronavirus update: U.S. COVID-19 cases climb above 2.9 million; ‘We’re still knee-deep in the first wave,’ Dr. Fauci warns Novavax stock rockets on news of $1.6 billion in funding from U.S. government’s accelerated vaccine program ‘Operation Warp Speed’The number of U.S. cases of the coronavirus illness COVID-19 climbed above 2.9 million on Tuesday, as Dr. Anthony Fauci warned Americans the country is “still knee deep in the first wave,” and reiterated his message to young people that they are not invulnerable.
5:25 a.m. July 4, 2020 - By Jaimy Lee
After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate FDA’s new guidelines for vaccine development ‘do not suggest that a widely usable vaccine will be available at ‘warp speed’ in 2020,’ says one analystThe path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of preliminary clinical data for two candidates and a rigorous new regulatory road map from the Food and Drug Administration.
2:12 a.m. July 1, 2020 - By Ciara Linnane
Coronavirus update: Pandemic is ‘not even close to being over,’ says WHO head, urging better testing — and face masks Micron Technology has a better-than-expected quarter thanks to a boom in demand for cloud computing during the pandemicThe coronavirus pandemic is “not even close to being over,” according to the head of the World Health Organization, and the worst is still to come, in what was a grim assessment of the state of affairs some six months after the first cases were reported in China.
2:12 a.m. June 30, 2020 - By Ciara Linnane
Coronavirus update: Global COVID-19 case tally tops 10 million and Florida, South Carolina and Nevada set daily records New Jersey to postpone allowing indoor dining ‘indefinitely’; AMC delays reopening of U.S. theaters by about two weeksThe number of confirmed cases of the coronavirus illness COVID-19 topped 10 million around the world and the death toll surpassed a half million over the weekend, and Florida, South Carolina and Nevada all recorded their highest number of new infections in a single day.
3:21 a.m. June 9, 2020 - By Ciara Linnane
Charlotte's Web to sponsor human trial to evaluate whether daily CBD use impacts the liverCharlotte's Web Holdings Inc. said Tuesday that it will sponsor ValidCare along with six other CBD brands in conducting a human trial to determine whether daily CBD use has any impact on the liver. ValidCare is a clinical trial outsourcing company. In a statement, the Boulder, Colorado-based company said the study is a response to Food and Drug Administration's public questions about CBD products and how they impact the human liver. "As the market share leader, anchored in science, sponsoring ValidCare's study made strategic sense for us," Chief Executive Deanie Elsner said in a statement. "This research will provide important clinical data to guide our entire industry while also showing the FDA we've heard their requests and are answering their questions with precise data." The FDA is the regulator of CBD because it approved a CBD-based drug, Epidiolex, for use in severe childhood epilepsy, but the agency is keen for full human trials to be conducted to evaluate the safety of the cannabis ingredient. Charlotte's Web said it is one of just seven companies to commit to the trial out of more than 100 that were invited to participate. U.S.-listed shares were not active premarket, but have fallen 10% in the year to date, while the Cannabis ETF has fallen 5% and the S&P 500 is flat.
10:06 a.m. June 4, 2020 - By Ciara Linnane
Coronavirus update: Global case tally climbs above 6.6 million and California reports a rise in infections amid protests and reopening Amazon is adding to its fleet of cargo jets at a time when aircraft values are depressed; Michaels Cos. earnings fall way shortThe number of confirmed cases of the coronavirus that causes COVID-19 rose past 6.6 million on Thursday, and California reported a rise in infections after weeks of slowing, raising concerns that the protests at the death of George Floyd, and the reopening of certain counties, are helping spread the illness.
10:27 a.m. June 3, 2020 - By Ciara Linnane
Coronavirus update: Global death toll tops 380,000 as Brazil records biggest one-day increase since start of outbreak As expected, Zoom Video posted blowout earnings as videoconferencing is proving popular during the pandemicThe global death toll from the coronavirus that causes COVID-19 rose above 380,000 on Wednesday after Brazil recorded its biggest one-day increase since the start of the outbreak, and protests about the death of George Floyd in Minnesota last week spread around the world.
11:12 a.m. June 2, 2020 - By Ciara Linnane
Coronavirus update: U.S. case tally tops 1.8 million; study finds face masks, social distancing effective at reducing infections Zoom Video will offer first look at how the pandemic has boosted its business later Tuesday, with Slack to follow on ThursdayThe number of Americans with confirmed case of the coronavirus that causes COVID-19 climbed above 1.8 million on Tuesday, amid concerns that protests about the death of George Floyd last week, and people gathering in groups as lockdowns are lifted, will spark a fresh wave of infections.
11:12 a.m. May 28, 2020 - By Ciara Linnane
Coronavirus update: U.S. marks grim milestone as Trump preps executive order on social-media companies HP’s printing business takes a hit as office workers stay home, while Dollar General and Dollar Tree enjoy sales boost The U.S. death toll from the coronavirus that causes COVID-19 rose above 101,000 on Thursday, one day after it exceeded the 100,000 level, a grim marker for the nation with the highest number of cases and deaths in the world.
2:15 p.m. May 27, 2020 - By Ciara Linnane
Coronavirus update: Global death toll climbs above 353,000; U.S. deaths surpass 100,000 Domino’s Pizza and Papa John’s enjoy strong sales bump, while Ralph Lauren’s sales falter with stores closedThe number of deaths from the coronavirus that causes COVID-19 rose above 353,000 on Wednesday, as the World Health Organization said the Americas are at the center of the pandemic following surges in infections in Brazil, Peru, Chile and others in the past few days.
2:30 a.m. May 21, 2020 - By Max A. Cherney
Aurora Cannabis makes its long-awaited push into the U.S. with Reliva CBD acquisition Aurora shares surge nearly 30% in the extended sessionOver a year after Aurora Cannabis Inc. executives started publicly talking about making a push into the U.S. market, the company has made its move: the $40 million all-stock purchase of a cannabidiol maker called Reliva.
2:08 a.m. May 21, 2020 - By Jaimy Lee
Moderna’s stock soars, then dips, after questions arise around the limited data shared about its COVID-19 vaccine Wall Street analysts largely view the clinical-trial data released by Moderna, however limited, as a positiveInvestors in Moderna Inc., the preclinical biotechnology company developing one of the front-running COVID-19 vaccines in the U.S., may face a volatile ride through the clinical trial process.
11:20 a.m. May 19, 2020 - By Ciara Linnane
Coronavirus update: U.S. death toll tops 91,000; Trump slams WHO, says he’s taking hydroxychloroquine to stave off COVID-19 Walmart cheers investors with blowout quarter; Southwest Airlines says demand is showing signs of improvementThe U.S. death toll from the coronavirus that causes COVID-19 rose above 91,000 on Tuesday, as President Donald Trump again threatened to cut off funding for the World Health Organization, accusing its leaders of failing to react quickly or aggressively enough at the start of the outbreak.
Browse topics:

Filter results by

Location

Us (597)

Europe (119)

Asia Pacific (110)

China (93)

Eu (92)

Latin America (18)

Link to MarketWatch's Slice.